Haemonetics' annual earnings are now projected to leap 26% in its current fiscal 2024 and rise another 6% in FY25 to $4.07 per share. Even better, FY24 and FY25 earnings estimates have remained higher over the last quarter which largely attributes to Haemonetics' strong buy rating.